MergerMay 21, 2026, 05:07 PM
VYNE Therapeutics to Merge with Yarrow Bioscience; Q3 '26 Close
AI Summary
VYNE Therapeutics Inc. announced a proposed reverse merger with Yarrow Bioscience, Inc., expected to close in Q3 2026, after which the combined entity will trade as YARW on NASDAQ. Yarrow, founded in 2025, is focused on developing novel therapies for thyroid autoimmune diseases, specifically advancing YB-101, a potential first-in-class anti-TSHR antibody for Graves’ Disease (GD) and Thyroid Eye Disease (TED). The company has secured $200 million in funding, including a pre-closing financing, providing a cash runway into 2028, and has received Fast Track Designation for its GD program.
Key Highlights
- VYNE Therapeutics to merge with Yarrow Bioscience in a reverse merger, expected to close in Q3 2026.
- The combined company will trade on NASDAQ as YARW, focusing on thyroid autoimmune diseases.
- Yarrow is advancing YB-101, an anti-TSHR antibody for Graves’ Disease and Thyroid Eye Disease.
- YB-101's Graves’ Disease program received FDA Fast Track Designation.
- Phase 2a/2b trial for Graves’ Disease expected to start Q2 2026; Phase 2a data in 2H 2027.
- Yarrow raised $200M, including pre-closing financing, for cash runway into 2028.
- Pre-merger VYNE stockholders to receive $0.34-$0.38 cash dividend per share.
- Pre-merger VYNE stockholders expected to own 3.0% of the combined company.
Price Impact
More from VYNE